Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.
Moises A HuamanJay S RavalJames H PaxtonGiselle S MosnaimBela PatelShweta AnjanBarry R MeisenbergAdam C LevineChristi E MarshallAnusha YaravaAarthi G ShenoySonya L HeathJudith S CurrierYuriko FukutaJanis E BlairEmily S SpivakJoann R PetriniPatrick B BroderickWilliam RauschMarieElena CordiscoJean HammelBenjamin GreenblattValerie C CluzetDaniel CruserKevin OeiMatthew AbinanteLaura L HammittCatherine G SutcliffeDonald N ForthalMartin S ZandEdward R CachaySeble G KassayeMalathi RamYing WangPiyali DasKaren LaneNichol A McBeeAmy L GawadNicky KarlenDaniel E FordOliver LaeyendeckerAndrew PekoszSabra L KleinStephan EhrhardtBryan LauSheriza N BakshDavid M ShadeArturo CasadevallDaniel F HanleyJiangda OuThomas J GniadekAlyssa ZimanShmuel ShohamKelly A GeboEvan M BlochAaron A R TobianDavid J SullivanJonathan M GerberPublished in: Transfusion (2023)
Outpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID-19.